Key PointsCoreWeave is a leading AI cloud provider with exceptional revenue growth, but the company remains unprofitable due to heavy borrowing.

3 Nasdaq-100 Stocks That Can Double, According to Wall Street

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) reported its third-quarter 2026 earnings and revenue, supported by continued growth in its transthyretin (TTR) franchise, particularly AMVUTTRA.

Alnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline 

(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) revealed earnings for its third quarter that Increases, from the same period last year

Alnylam Pharmaceuticals Inc. Reports Advance In Q3 Bottom Line 

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) on Friday reported its investigational drug Brezosiran, previously known as ALN-HTT02, reduced mutant huntingtin protein levels in initial Phase 1b trial in Huntington's disease.

Alnylam's Brezosiran Lowers Mutant Huntingtin In Phase 1b Huntington's Trial 

(RTTNews) - Alnylam Pharmaceuticals (ALNY) reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington's disease. ALN-HTT02 will be developed under the International Nonproprietary Nam

Alnylam Reports Positive Initial Phase 1b Results For ALN-HTT02 

Key PointsAlnylam's stock has plunged more than 40% this year, but the company's financials look great.

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc. News